New York State Teachers Retirement System (NYSTRS)
NBIX icon

New York State Teachers Retirement System (NYSTRS)’s Neurocrine Biosciences NBIX Stock Holding History

New York State Teachers Retirement System (NYSTRS)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5M Sell
85,892
-3,818
-4% -$566K 0.03% 431
2026
Q1 		$11.8M Sell
89,710
-5,921
-6% -$786K 0.02% 492
2025
Q4 		$13.6M Sell
95,631
-3,048
-3% -$442K 0.03% 445
2025
Q3 		$13.9M Buy
98,679
+4,917
+5% +$666K 0.03% 441
2025
Q2 		$11.8M Sell
93,762
-14,719
-14% -$1.69M 0.02% 474
2025
Q1 		$12M Sell
108,481
-2,055
-2% -$260K 0.03% 452
2024
Q4 		$15.1M Sell
110,536
-4,514
-4% -$558K 0.03% 410
2024
Q3 		$13.3M Buy
115,050
+2,017
+2% +$277K 0.03% 468
2024
Q2 		$15.6M Buy
113,033
+9,723
+9% +$1.33M 0.03% 404
2024
Q1 		$14.2M Buy
103,310
+1,541
+2% +$210K 0.03% 447
2023
Q4 		$13.4M Buy
101,769
+4,780
+5% +$550K 0.03% 443
2023
Q3 		$10.9M Buy
96,989
+740
+0.8% +$77.9K 0.03% 474
2023
Q2 		$9.08M Hold
96,249
– – 0.02% 560
2023
Q1 		$9.74M Sell
96,249
-1,055
-1% -$110K 0.02% 530
2022
Q4 		$11.6M Buy
97,304
+18,041
+23% +$2.11M 0.03% 468
2022
Q3 		$8.42M Buy
79,263
+4,289
+6% +$435K 0.02% 547
2022
Q2 		$7.31M Buy
74,974
+16,200
+28% +$1.5M 0.02% 624
2022
Q1 		$5.51M Sell
58,774
-1,275
-2% -$108K 0.01% 782
2021
Q4 		$5.11M Buy
60,049
+20,198
+51% +$1.86M 0.01% 827
2021
Q3 		$3.82M Sell
39,851
-83
-0.2% -$7.84K 0.01% 932
2021
Q2 		$3.89M Buy
39,934
+19,734
+98% +$1.89M 0.01% 924
2021
Q1 		$1.96M Buy
+20,200
New +$2.12M ﹤0.01% 1152
2020
Q4 		– Sell
-1,900
Closed -$183K – 1643
2020
Q3 		$183K Buy
1,900
+1,400
+280% +$162K ﹤0.01% 1495
2020
Q2 		$61K Buy
+500
New +$55.3K ﹤0.01% 1545

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS)'s NBIX Position: Q2 2026 in Review

New York State Teachers Retirement System (NYSTRS) reduced its Neurocrine Biosciences (NBIX) stake by 4.3% in Q2 2026, selling an estimated $566K and leaving 85,892 shares worth $14.5M. The position accounts for 0.03% of the portfolio, ranked #431.

New York State Teachers Retirement System (NYSTRS) first reported a position in NBIX in Q2 2020 and has held it in 24 quarters since. The position peaked at $15.6M in Q2 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • New York State Teachers Retirement System (NYSTRS) held 85,892 shares of Neurocrine Biosciences worth $14.5M as of Q2 2026.
  • New York State Teachers Retirement System (NYSTRS) sold 3,818 Neurocrine Biosciences shares in Q2 2026, an estimated $566K.
  • Neurocrine Biosciences made up 0.03% of New York State Teachers Retirement System (NYSTRS)'s portfolio in Q2 2026, its #431 holding.
  • New York State Teachers Retirement System (NYSTRS) first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 24 quarters since.
  • New York State Teachers Retirement System (NYSTRS)'s Neurocrine Biosciences position peaked at $15.6M in Q2 2024.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on New York State Teachers Retirement System (NYSTRS)'s 13F filing for Q2 2026, filed 23 Jul 2026.